Clinical research on ICI therapy is advancing (Table 1), starting with the most well-known ICMs CTLA-4 and PD-1, where blocking signalling through these molecules has been shown to promote T cell infiltration and expansion at the tumour site and to activate intratumoral natural killer (NK) cells [11,12,13,14]. This evidence concerns the gene PDCD1 and neoplasm.